Skip to content

Study · Non-randomized trial · n = 3 · 2026

4 results

Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men.

Naveed A, Lippincott MF, Stamou M, Balasubramanian R, Bryant NK, Seminara SB

Hormones (Athens, Greece)2 Jun 2026

PMID42230485 (opens in a new tab)PMCIDPMC13386888 (opens in a new tab)DOI10.1007/s42000-026-00795-y (opens in a new tab)PepBankPUB-42230485
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

PurposeKisspeptin stimulates gonadotropin-releasing hormone (GnRH) release and, by extension, gonadotropin secretion. Although continuous kisspeptin administration has been shown to dampen kisspeptin-induced GnRH release in non-human primates [1, 2], this has not been replicated in the limited human studies reported to date. The objective of this study was to examine the effects of continuous kisspeptin administration on luteinizing hormone (LH) secretion in healthy men.MethodsThree healthy adult men received a continuous intravenous infusion of kisspeptin-10 at a dose of 12.5 mcg/kg/h for 24 h and underwent frequent blood sampling to characterize the effect on reproductive hormones.ResultsContinuous administration of kisspeptin resulted in an immediate increase in LH concentrations, from a baseline of 2.8-3.8 mIU/mL to the highest values of 17.5-30.6 mIU/mL (5- to eightfold above baseline), reached within 12-20 h of infusion onset. LH concentrations subsequently declined by 13-47% from max to end of the infusion, settling at 10.7-22.8 mIU/mL. FSH and testosterone rose modestly in parallel.ConclusionWhile kisspeptin boluses have been employed to probe GnRH pulse generation, continuous infusion of kisspeptin is a complementary physiologic tool used to study dynamic changes in GnRH-induced LH secretion. Further studies are warranted to further elucidate the physiologic response of the kisspeptin receptor to non-pulsatile ligand administration.Clinical trial registrationNCT01438073 (August 24, 2011).
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In three healthy men, continuous intravenous kisspeptin‑10 infusion raised LH from a baseline of 2.8-3.8 mIU/mL to peak values of 17.5-30.6 mIU/mL within 12-20 h.

    In plain wordsIn three healthy men, a 24-hour kisspeptin‑10 drip raised luteinizing hormone five- to eightfold above baseline.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseLH concentration during infusion
    Study

    n = 3

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    12.5 mcg/kg/h · intravenous · 24 hAs given in this study (human).

    Measurements

    LH baseline
    2.8 to 3.8 mIU/mL
    baseline
    LH peak
    17.5 to 30.6 mIU/mL
    highest values

    Source sentences

    Summary
    Continuous administration of kisspeptin resulted in an immediate increase in LH concentrations, from a baseline of 2.8-3.8 mIU/mL to the highest values of 17.5-30.6 mIU/mL (5- to eightfold above baseline), reached within 12-20 h of infusion onset.
    1 context sentence
    Summary · context
    Three healthy adult men received a continuous intravenous infusion of kisspeptin-10 at a dose of 12.5 mcg/kg/h for 24 h and underwent frequent blood sampling to characterize the effect on reproductive hormones.
  2. 02HumanNon-randomized trialEfficacy outcome

    In three healthy men, LH fell by 13-47% from its maximum to the end of the continuous kisspeptin‑10 infusion, settling at 10.7-22.8 mIU/mL.

    In plain wordsIn three healthy men, luteinizing hormone fell back partly during the continuing kisspeptin‑10 drip but stayed above baseline.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseLH decline from maximum to end of infusion
    Study

    n = 3

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    12.5 mcg/kg/h · intravenous · 24 hAs given in this study (human).

    Measurements

    LH decline from max
    13 to 47%
    end of infusion
    LH at end of infusion
    10.7 to 22.8 mIU/mL
    end of infusion

    Source sentences

    Summary
    LH concentrations subsequently declined by 13-47% from max to end of the infusion, settling at 10.7-22.8 mIU/mL.
    1 context sentence
    Summary · context
    Three healthy adult men received a continuous intravenous infusion of kisspeptin-10 at a dose of 12.5 mcg/kg/h for 24 h and underwent frequent blood sampling to characterize the effect on reproductive hormones.
  3. 03HumanNon-randomized trialEfficacy outcome

    In three healthy men, FSH rose modestly in parallel with LH during continuous kisspeptin‑10 infusion.

    In plain wordsIn three healthy men, follicle-stimulating hormone rose a little during the kisspeptin‑10 drip.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseFSH concentration
    Study

    n = 3

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    12.5 mcg/kg/h · intravenous · 24 hAs given in this study (human).

    Source sentences

    Summary
    FSH and testosterone rose modestly in parallel.
    1 context sentence
    Summary · context
    Three healthy adult men received a continuous intravenous infusion of kisspeptin-10 at a dose of 12.5 mcg/kg/h for 24 h and underwent frequent blood sampling to characterize the effect on reproductive hormones.
  4. 04HumanNon-randomized trialEfficacy outcome

    In three healthy men, testosterone rose modestly in parallel with LH during continuous kisspeptin‑10 infusion.

    In plain wordsIn three healthy men, testosterone rose a little during the kisspeptin‑10 drip.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseTestosterone concentration
    Study

    n = 3

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    12.5 mcg/kg/h · intravenous · 24 hAs given in this study (human).

    Source sentences

    Summary
    FSH and testosterone rose modestly in parallel.
    1 context sentence
    Summary · context
    Three healthy adult men received a continuous intravenous infusion of kisspeptin-10 at a dose of 12.5 mcg/kg/h for 24 h and underwent frequent blood sampling to characterize the effect on reproductive hormones.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01438073

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

Massachusetts General Hospitaln = 96Sept 2011 to Apr 2016

Hypogonadotropic Hypogonadism · Healthy Postmenopausal Women · Agonadism

Trial pageClinicalTrials.govUpdated 11 Jul 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.